---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-024952"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:09:46.443728+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allarity closes $20M non-convertible debt with Streeterville; extends cash runway to mid-2028

## Summary
- Closed $20M non-convertible debt financing with Streeterville Capital via two promissory notes: $10.93M and $10M.
- Net proceeds extend cash runway into summer 2028; funds Phase 2 ovarian cancer trial and FDA preparation.
- Proceeds also support pivotal trial prep, companion diagnostic strategy, and potential expansion into other WNT-driven tumors.
- Stenoparib has shown durable clinical benefit; some patients on therapy >30 months in Phase 2.

## SEC filing metadata
- accession: 0001213900-26-024952
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026024952/0001213900-26-024952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026024952/ea0280539-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-024952
- JSON: https://secwatch.observer/filing/0001213900-26-024952.json
- Plain text: https://secwatch.observer/filing/0001213900-26-024952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.